|
1
|
Russo A, Franchina T, Ricciardi GR, Picone
A, Ferraro G, Zanghì M, Toscano G, Giordano A and Adamo V: A decade
of EGFR inhibition in EGFR-mutated non small cell lung cancer
(NSCLC): Old successes and future perspectives. Oncotarget.
6:26814–26825. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gazdar AF: Activating and resistance
mutations of EGFR in non-small-cell lung cancer: Role in clinical
response to EGFR tyrosine kinase inhibitors. Oncogene. 28:(Suppl
1). S24–S31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moran C: Importance of molecular features
of non-small cell lung cancer for choice of treatment. Am J Pathol.
178:1940–1948. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Massarelli E, Johnson FM, Erickson HS,
Wistuba II and Papadimitrakopoulou V: Uncommon epidermal growth
factor receptor mutations in non-small cell lung cancer and their
mechanisms of EGFR tyrosine kinase inhibitors sensitivity and
resistance. Lung Cancer. 80:235–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Keedy VL, Temin S, Somerfield MR, Beasley
MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and
Giaccone G: American Society of Clinical Oncology provisional
clinical opinion: Epidermal growth factor receptor (EGFR) Mutation
testing for patients with advanced non-small-cell lung cancer
considering first-line EGFR tyrosine kinase inhibitor therapy. J
Clin Oncol. 29:2121–2127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stinchcombe TE: Novel agents in
development for advanced non-small cell lung cancer. Ther Adv Med
Oncol. 6:240–253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kwak EL, Sordella R, Bell DW,
Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR,
Fidias P, Lynch TJ, et al: Irreversible inhibitors of the EGF
receptor may circumvent acquired resistance to gefitinib. Proc Natl
Acad Sci USA. 102:7665–7670. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Engelman JA, Zejnullahu K, Gale CM,
Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov
GN, Bradner JE, et al: PF00299804, an irreversible pan-ERBB
inhibitor, is effective in lung cancer models with EGFR and ERBB2
mutations that are resistant to gefitinib. Cancer Res.
67:11924–11932. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li D, Ambrogio L, Shimamura T, Kubo S,
Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A,
Himmelsbach F, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor
highly effective in preclinical lung cancer models. Oncogene.
27:4702–4711. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miller VA, Hirsh V, Cadranel J, Chen YM,
Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, et al: Afatinib
versus placebo for patients with advanced, metastatic
non-small-cell lung cancer after failure of erlotinib, gefitinib,
or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase
2b/3 randomised trial. Lancet Oncol. 13:528–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sequist LV, Besse B, Lynch TJ, Miller VA,
Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, et
al: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase
inhibitor: Results of a phase II trial in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 28:3076–3083. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reckamp KL, Giaccone G, Camidge DR,
Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell
AK, Gernhardt D, et al: A phase 2 trial of dacomitinib
(PF-00299804), an oral, irreversible pan-HER (human epidermal
growth factor receptor) inhibitor, in patients with advanced
non-small cell lung cancer after failure of prior chemotherapy and
erlotinib. Cancer. 120:1145–1154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Walter AO, Sjin RT, Haringsma HJ, Ohashi
K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, et al:
Discovery of a mutant-selective covalent inhibitor of EGFR that
overcomes T790M-mediated resistance in NSCLC. Cancer Discov.
3:1404–1415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sequist LV, Soria JC, Goldman JW, Wakelee
HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard
GR, Dziadziuszko R, et al: Rociletinib in EGFR-mutated
non-small-cell lung cancer. N Engl J Med. 372:1700–1709. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gendreau SB, Ventura R, Keast P, Laird AD,
Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, et al:
Inhibition of the T790M gatekeeper mutant of the epidermal growth
factor receptor by EXEL-7647. Clin Cancer Res. 13:3713–3723. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Somwar R, Shum D, Djaballah H and Varmus
H: Identification and preliminary characterization of novel small
molecules that inhibit growth of human lung adenocarcinoma cells. J
Biomol Screen. 14:1176–1184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang HY, Hsu MK, Wang KH, Tseng CP, Chen
FC and Hsu JT: Non-small-cell lung cancer cells combat epidermal
growth factor receptor tyrosine kinase inhibition through immediate
adhesion-related responses. Onco Targets Ther. 9:2961–2973. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Greulich H, Chen TH, Feng W, Jänne PA,
Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR,
et al: Oncogenic transformation by inhibitor-sensitive and
-resistant EGFR mutants. PLoS Med. 2:e3132005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Carey KD, Garton AJ, Romero MS, Kahler J,
Thomson S, Ross S, Park F, Haley JD, Gibson N and Sliwkowski MX:
Kinetic analysis of epidermal growth factor receptor somatic mutant
proteins shows increased sensitivity to the epidermal growth factor
receptor tyrosine kinase inhibitor, erlotinib. Cancer Res.
66:8163–8171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin WH, Song JS, Lien TW, Chang CY, Wu SH,
Huang YW, Chang TY, Fang MY, Yen KJ, Chen CH, et al: A
high-throughput cell-based screening for L858R/T790M mutant
epidermal growth factor receptor inhibitors. Anticancer Res.
32:147–151. 2012.PubMed/NCBI
|
|
26
|
Goshima N, Kawamura Y, Fukumoto A, Miura
A, Honma R, Satoh R, Wakamatsu A, Yamamoto J, Kimura K, Nishikawa
T, et al: Human protein factory for converting the transcriptome
into an in vitro-expressed proteome. Nat Methods. 5:1011–1017.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Di Nicolantonio F, Arena S, Gallicchio M
and Bardelli A: Isogenic mutant human cells: A new tool for
personalized cancer medicine. Cell Cycle. 9:20–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
